Wegovy vs Mounjaro: Which 1.7mg Equivalent Works Best?
Understanding 1.7mg Wegovy Equivalent in Mounjaro Dosing
When comparing 1.7mg Wegovy equivalent in Mounjaro, it's essential to understand that these prescription weight loss treatments follow different dosing protocols entirely. Wegovy 1.7mg represents weeks 13-16 of a structured five-step escalation, positioning patients just before reaching the 2.4mg maintenance dose. Mounjaro, containing tirzepatide rather than semaglutide, follows its own distinct schedule with 2.5mg, 5mg, 7.5mg, 10mg, and 15mg options. Both medicines require clinical assessment and prescription-only access through registered UK pharmacies.
The key difference lies in their mechanisms: Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 pathways as a dual agonist. This means there isn't a direct 1.7mg Wegovy equivalent in Mounjaro—rather, your prescriber will determine the appropriate Mounjaro dose based on your individual response and treatment goals. Both treatments are available from EverydayMeds following our comprehensive clinical assessment, ensuring you receive the most suitable option for your circumstances.
Wegovy 1.7mg Pricing and Mounjaro Cost Comparison
Wegovy 1.7mg costs £139.99 per pen at EverydayMeds, representing exceptional value for this penultimate escalation dose. New customers can apply discount code FIRST40 at checkout, whilst returning customers benefit from code DOSE25 for continued savings. Our Elevate Duo bundle combines 1.7mg and 2.4mg pens for £369.99, providing a seamless transition to maintenance therapy. For patients requiring extended 1.7mg treatment, our Consistency 1.7mg bundle offers two pens for £309.99.
Mounjaro pricing follows a different structure due to its unique dosing schedule, with costs varying by prescribed strength. Both treatments represent significant investments in your health, backed by extensive clinical evidence and MHRA approval. When comparing the 1.7mg Wegovy equivalent in Mounjaro costs, consider the complete treatment journey rather than individual pen prices. EverydayMeds provides transparent pricing for both options, with expert clinical guidance to ensure optimal value for your specific treatment needs.
Clinical Evidence: Wegovy vs Mounjaro Weight Management
Clinical evidence for Wegovy comes primarily from the STEP trial programme, where patients taking 2.4mg semaglutide alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). The 1.7mg dose represents a stepping stone toward this maintenance level, with patients typically experiencing progressive results during weeks 13-16. STEP trial participants demonstrated sustained weight management when continuing treatment long-term.
Mounjaro's evidence base stems from the SURMOUNT trials, showing tirzepatide's dual-agonist mechanism may produce different response patterns compared to GLP-1-only treatments. However, these trials used different methodologies, patient populations, and endpoints, making direct comparison inappropriate. Both treatments require prescription-only access and must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
How Wegovy 1.7mg Works in Your Weight Management Journey
Wegovy 1.7mg functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones to reduce appetite and promote satiety after smaller meals. At this dose level—weeks 13-16 of treatment—patients often notice enhanced appetite control and reduced food cravings compared to earlier escalation phases. The medication works on brain appetite centres, potentially making it easier to maintain the reduced-calorie diet essential for successful weight management. This 1.7mg dose prepares your system for the 2.4mg maintenance level, where clinical trials demonstrated optimal long-term results. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system ensures consistent therapeutic levels throughout your treatment week.
Ordering Process: From Assessment to Delivery
Accessing Wegovy 1.7mg or finding your Mounjaro equivalent begins with EverydayMeds' comprehensive 3-minute online clinical assessment. Our qualified prescribers review your medical history, current medications, and weight management goals within three working days (or 24 hours with express service). Once approved, your prescription-only medicine ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. Our GPhC-registered pharmacy (#9012878) ensures full UK compliance and professional oversight of your treatment. Payment processing accepts all major cards, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied at checkout for optimal pricing.
Storage and Practical Considerations for Treatment Success
Wegovy offers significant storage advantages over Mounjaro, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. This flexibility proves invaluable for travel, work schedules, or unexpected situations where refrigeration isn't immediately available. The FlexTouch pen design allows for precise 1.7mg dosing with minimal injection discomfort, typically administered weekly on the same day. Dose escalation from 1.7mg to 2.4mg should occur only after completing the full four-week period, as skipping or accelerating doses increases side effect risks. Store unused pens in their original packaging at 2-8°C, protecting from light and freezing temperatures that could damage the medication.
Transitioning from 1.7mg: Your Path to Maintenance Therapy
The 1.7mg Wegovy equivalent in Mounjaro conversation becomes particularly relevant when planning your transition to maintenance therapy. Wegovy patients typically progress to 2.4mg after completing four weeks at 1.7mg, representing the evidence-based maintenance dose from STEP trials. This transition period often coincides with accelerated weight management results as your body adapts to therapeutic semaglutide levels. Mounjaro patients follow their prescriber's guidance for optimal dose escalation, which may involve different timelines and target doses based on individual response.
Our Elevate Duo bundle (1.7mg + 2.4mg) costs £369.99, specifically designed for patients approaching this critical transition phase. Many customers find this transition period ideal for establishing long-term habits around diet, exercise, and injection routine consistency. Whether continuing with Wegovy or switching to Mounjaro, maintaining regular prescriber contact ensures optimal dose adjustments and side effect management throughout your weight management journey.
Expert Guidance: Choosing Between Wegovy and Mounjaro Options
Selecting between 1.7mg Wegovy and its Mounjaro equivalent requires expert clinical assessment rather than generic comparisons. EverydayMeds' qualified prescribers consider your medical history, previous weight management attempts, current medications, and individual response patterns when recommending treatment options. Some patients respond optimally to Wegovy's GLP-1 mechanism, whilst others may benefit from Mounjaro's dual-agonist approach—there's no universal "better" choice without clinical context. Our comprehensive assessment process ensures you receive evidence-based recommendations rather than one-size-fits-all prescribing.
Both treatments are available from EverydayMeds with identical professional oversight, cold-chain delivery, and ongoing support throughout your weight management journey. Your prescriber can help determine which treatment aligns best with your lifestyle, budget, and clinical needs. Book your confidential assessment today using code FIRST40 (new customers) or DOSE25 (returning customers) at https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your professionally-supervised weight management programme with the UK's trusted prescription service.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
